Cargando…

Differential MSC activation leads to distinct mononuclear leukocyte binding mechanisms

Advances in the field of Multipotent Mesenchymal Stromal cell (MSC) biology have demonstrated that MSCs can improve disease outcome when ‘activated' to exert immunomodulatory effects. However, the precise mechanisms modulating MSC-immune cells interactions remain largely elusive. In here, we ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Kota, Daniel J., DiCarlo, Bryan, Hetz, Robert A., Smith, Philippa, Cox, Charles S., Olson, Scott D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3972508/
https://www.ncbi.nlm.nih.gov/pubmed/24691433
http://dx.doi.org/10.1038/srep04565
_version_ 1782309601289437184
author Kota, Daniel J.
DiCarlo, Bryan
Hetz, Robert A.
Smith, Philippa
Cox, Charles S.
Olson, Scott D.
author_facet Kota, Daniel J.
DiCarlo, Bryan
Hetz, Robert A.
Smith, Philippa
Cox, Charles S.
Olson, Scott D.
author_sort Kota, Daniel J.
collection PubMed
description Advances in the field of Multipotent Mesenchymal Stromal cell (MSC) biology have demonstrated that MSCs can improve disease outcome when ‘activated' to exert immunomodulatory effects. However, the precise mechanisms modulating MSC-immune cells interactions remain largely elusive. In here, we activated MSC based on a recent polarization paradigm, in which MSCs can be polarized towards a pro- or anti-inflammatory phenotype depending on the Toll-like receptor stimulated, to dissect the mechanisms through which MSCs physically interact with and modulate leukocytes in this context. Our data show that MSCs activated through the Toll-like receptor (TLR) 4 pathway increased VCAM-1 and ICAM-1 dependent binding of leukocytes. On the other hand, TLR3 stimulation strongly increases leukocytes affinity to MSC comparatively, through the formation of cable-like hyaluronic acid structures. In addition, TLR4 activation elicited secretion of pro-inflammatory mediators by MSCs, whereas TLR3-activated MSCs displayed a milder pro-inflammatory phenotype, similar to inactivated MSCs. However, the differently activated MSCs maintained their ability to suppress leukocyte activation at similar levels in our in vitro model, and this immunomodulatory property was shown here to be partially mediated by prostaglandin. These results reinforce the concept that alternate activation profiles control MSC responses and may impact the therapeutic use of MSCs.
format Online
Article
Text
id pubmed-3972508
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-39725082014-04-02 Differential MSC activation leads to distinct mononuclear leukocyte binding mechanisms Kota, Daniel J. DiCarlo, Bryan Hetz, Robert A. Smith, Philippa Cox, Charles S. Olson, Scott D. Sci Rep Article Advances in the field of Multipotent Mesenchymal Stromal cell (MSC) biology have demonstrated that MSCs can improve disease outcome when ‘activated' to exert immunomodulatory effects. However, the precise mechanisms modulating MSC-immune cells interactions remain largely elusive. In here, we activated MSC based on a recent polarization paradigm, in which MSCs can be polarized towards a pro- or anti-inflammatory phenotype depending on the Toll-like receptor stimulated, to dissect the mechanisms through which MSCs physically interact with and modulate leukocytes in this context. Our data show that MSCs activated through the Toll-like receptor (TLR) 4 pathway increased VCAM-1 and ICAM-1 dependent binding of leukocytes. On the other hand, TLR3 stimulation strongly increases leukocytes affinity to MSC comparatively, through the formation of cable-like hyaluronic acid structures. In addition, TLR4 activation elicited secretion of pro-inflammatory mediators by MSCs, whereas TLR3-activated MSCs displayed a milder pro-inflammatory phenotype, similar to inactivated MSCs. However, the differently activated MSCs maintained their ability to suppress leukocyte activation at similar levels in our in vitro model, and this immunomodulatory property was shown here to be partially mediated by prostaglandin. These results reinforce the concept that alternate activation profiles control MSC responses and may impact the therapeutic use of MSCs. Nature Publishing Group 2014-04-02 /pmc/articles/PMC3972508/ /pubmed/24691433 http://dx.doi.org/10.1038/srep04565 Text en Copyright © 2014, Macmillan Publishers Limited. All rights reserved http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. The images in this article are included in the article's Creative Commons license, unless indicated otherwise in the image credit; if the image is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the image. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
spellingShingle Article
Kota, Daniel J.
DiCarlo, Bryan
Hetz, Robert A.
Smith, Philippa
Cox, Charles S.
Olson, Scott D.
Differential MSC activation leads to distinct mononuclear leukocyte binding mechanisms
title Differential MSC activation leads to distinct mononuclear leukocyte binding mechanisms
title_full Differential MSC activation leads to distinct mononuclear leukocyte binding mechanisms
title_fullStr Differential MSC activation leads to distinct mononuclear leukocyte binding mechanisms
title_full_unstemmed Differential MSC activation leads to distinct mononuclear leukocyte binding mechanisms
title_short Differential MSC activation leads to distinct mononuclear leukocyte binding mechanisms
title_sort differential msc activation leads to distinct mononuclear leukocyte binding mechanisms
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3972508/
https://www.ncbi.nlm.nih.gov/pubmed/24691433
http://dx.doi.org/10.1038/srep04565
work_keys_str_mv AT kotadanielj differentialmscactivationleadstodistinctmononuclearleukocytebindingmechanisms
AT dicarlobryan differentialmscactivationleadstodistinctmononuclearleukocytebindingmechanisms
AT hetzroberta differentialmscactivationleadstodistinctmononuclearleukocytebindingmechanisms
AT smithphilippa differentialmscactivationleadstodistinctmononuclearleukocytebindingmechanisms
AT coxcharless differentialmscactivationleadstodistinctmononuclearleukocytebindingmechanisms
AT olsonscottd differentialmscactivationleadstodistinctmononuclearleukocytebindingmechanisms